| Name | Title | Contact Details |
|---|---|---|
Ana Schrank |
Chief Financial Officer | Profile |
Robert Dickey |
Interim Chief Financial Officer | Profile |
Robert Dickey |
Interim Chief Financial Officer | Profile |
Matt Willmon |
Vice President, Total Rewards | Profile |
Eric Olivares |
Head of Research And Development | Profile |
twoXAR is an artificial intelligence-driven drug discovery company.
Biotix Holdings is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
Benitec is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference (RNAi) with gene therapy with a goal of providing sustained, long-lasting silencing of disease-causing genes from a single administration.
Bayer and CRISPR Therapeutics have entered into an agreement to create Casebia to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise and relevant disease know-how. It is the first long-term strategic partnership of its kind to make a substantial investment in the development of target delivery systems in an effort to bring systemic in vivo CRISPR-Cas9 gene editing technology applications to patients.
Cypress Bioscience, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.